Intramuscular Neostigmine and Glycopyrrolate Safely Accelerated Bowel Evacuation in Patients with Spinal Cord Injury and Defecatory Disorders

Stone JM, Nino Murcia M, Wolfe VA, Perkash I (1990) Chronic gastrointestinal problems in spinal cord injury patients: a prospective analysis. Am J Gastroenterol 85:1114–1119

Singal AK, Rosman AS, Bauman WA, Korsten MA (2006) Recent concepts in the management of bowel problems after spinal cord injury. Adv Med Sci 51:15–22

Stiens SA, Fajardo NR, Korsten MA (2003) The gastrointestinal system after spinal cord injury. In: Lin V (ed) Spinal cord medicine. Demos Medical Publishing, New York, pp 321–348

Ponec RJ, Saunders MD, Kimmey MB (1999) Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 341:137–141

Eisen GM, Baron TH, Dominitz JA, Faigel DO, Goldstein JL, Johanson JF, Mallery JS, Raddawi HM, Vargo JJ, Waring JP, Fanelli RD, Wheeler Harbaugh J (2002) Acute colonic pseudo-obstruction. Gastrointest Endosc 56:789–792

Penner RM, Jacka MJ, Brindley PG (2005) Best evidence in critical care medicine: medical therapy of acute colonic pseudo-obstruction: a moving experience. Can J Anaesth 52:542–543

Saunders MD, Kimmey MB (2005) Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther 22:917–925

Korsten MA, Rosman AS, Ng A, Cavusoglu E, Spungen AM, Radulovic M, Wecht J, Bauman WA (2005) Infusion of neostigmine-glycopyrrolate for bowel evacuation in persons with spinal cord injury. Am J Gastroenterol 100:1560–1565

Package insert for neostigmine methylsulfate (2005) Sicor Pharmaceuticals, Irvine, CA

Stiens SA, Luttrel W, Binard JE (1998) Polyethylene glycol versus vegetable oil based bisacodyl suppositories to initiate side-lying bowel care: a clinical trial in persons with spinal cord injury. Spinal Cord 36:777–781

Taylor P (2006) Anticholinesterase agents. In: Brunton LL (ed) Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 201–216

Taylor P (2006) Agents acting at the neuromuscular junction and autonomic ganglia. In: Brunton LL (ed) Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, p 227

Brown JH, Taylor P (2006) Muscarinic receptor agonists and antagonists. In: Brunton LL (ed) Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, p 197

Wilkins JL, Hardcastle JD, Mann CV, Kaufman L (1970) Effects of neostigmine and atropine on motor activity of ileum, colon, and rectum of anaesthetized subjects. Br Med J 1:793–794

Child CS (1984) Prevention of neostigmine-induced colonic activity. A comparison of atropine and glycopyrronium. Anaesthesia 39:1083–1085

Broggini M, Benvenuti C, Botta V, Fossati A, Valenti M (1991) Bioavailability of intranasal neostigmine: comparison with intravenous route. Meth Find Exp Clin Pharmacol 13:193–198

Sghirlanzoni A, Pareyson D, Benvenuti C, Cei G, Cosi V, Lombardi M, Nicora M, Ricciardi R, Cornelio F (1992) Efficacy of intranasal administration of neostigmine in myasthenic patients. J Neurol 239:165–169

Di Costanzo A, Toriello A, Mannara C, Benvenuti C, Tedeschi G (1993) Intranasal versus intravenous neostigmine in myasthenia gravis: assessment by computer analysis of saccadic eye movements. Clin Neuropharmacol 16:511–517

Ricciardi R, Rossi B, Nicora M, Sghirlanzoni A, Muratorio A (1991) Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation. J Neurol Neurosurg Psychiatry 54:1061–1062